Stanford researchers have developed a targeted antisense oligonucleotide (ASO) platform to restore physiological regulation of DYRK1A, a key driver of neurodevelopmental and neurodegenerative pathology in Down syndrome (Trisomy 21) and other tauopathies.
Stanford scientists have developed Q-DOAS (Quantitative Detection of Oligomer and Amyloid Seeds), a plate reader-based fluorescence quenching assay designed to track the formation of early-stage toxic oligomers and amyloid seeds in real-time.
Over 1 in 3 people are affected by neurological conditions worldwide. Pharmacological and surgical treatment options may be limited due to access, side effects, and reduced therapeutic efficacy.
Stanford researchers have developed a new therapeutic approach to protect neurons and promote axon regeneration by restoring mitochondrial transport within axons, a key process disrupted in many neurodegenerative diseases.
Stanford scientists have developed Plate-C, a high-throughput screening platform that captures genome-wide 3D chromatin architecture as a comprehensive cellular phenotype.
Stanford researchers have patented methods to improve phagocytosis, the process by which macrophages clear protein aggregates, dying cells, and debris, to treat age-related diseases.
Researchers in the Wyss-Coray Lab are investigating a potential therapeutic antibody to treat lysosomal storage disorders and other related neurodegenerative diseases.
The blood-brain barrier is a huge challenge when it comes to the delivery of therapeutic proteins to treat genetic diseases, injury, and neurodegenerative diseases.
To date, there are no treatments to restore neurologic function for the 7 million US patients suffering from chronic ischemic stroke. NR1 therapy provides a novel treatment for this unmet need.
A common hurdle for many drug delivery applications is getting the desired compounds to the targeted cells or receptors. Additional barriers of achieving the therapeutic drug concentration and necessary drug diffusion are also present even after successful targeted delivery.
Recent studies have linked microglia damage to various neurodegenerative and aging brain diseases. Relatedly, bone marrow transplantation has been shown to result in incorporation of macrophages into the brain, but the incorporation is variable, slow and inefficient.
Researchers at Stanford have found that nascent polypeptide-associated complex (NAC) and the apical domain of CCT1, as well as peptide fragments and fusion proteins containing them, can be used to suppress pathological protein aggregation.
Dr. Stanley Cohen and colleagues have identified small molecular compounds that may be useful in the treatment of nucleotide repeat diseases. A well-known nucleotide repeat disorder is Huntington's disease.
The Bronte-Stewart lab has designed an algorithm for calculating neural activity burst duration to better manage closed loop deep brain stimulation in patients with Parkinson's disease.
Stanford researchers have proposed the use of a conductive graphene scaffold (CGS) as a biocompatible scaffold for growth of neural tissues. The high conductivity enables the use of electrical stimulation to control the development of induced pluripotent stem cells (iPSCs).